These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Depletion of butyrate-producing microbes of the Firmicutes predicts nonresponse to FMT therapy in patients with recurrent Tian H; Cui J; Ye C; Zhao J; Yang B; Xu Y; Ji S; Wang L; Lv X; Ma C; Zhou S; Li N; Wang X; Qin H; Chen Q Gut Microbes; 2023; 15(1):2236362. PubMed ID: 37469017 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379 [TBL] [Abstract][Full Text] [Related]
12. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies. Berry P; Khanna S BioDrugs; 2023 Nov; 37(6):757-773. PubMed ID: 37493938 [TBL] [Abstract][Full Text] [Related]
13. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study. Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G; Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430 [TBL] [Abstract][Full Text] [Related]
14. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. McGovern BH; Ford CB; Henn MR; Pardi DS; Khanna S; Hohmann EL; O'Brien EJ; Desjardins CA; Bernardo P; Wortman JR; Lombardo MJ; Litcofsky KD; Winkler JA; McChalicher CWJ; Li SS; Tomlinson AD; Nandakumar M; Cook DN; Pomerantz RJ; Auninš JG; Trucksis M Clin Infect Dis; 2021 Jun; 72(12):2132-2140. PubMed ID: 32255488 [TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial. Sims MD; Khanna S; Feuerstadt P; Louie TJ; Kelly CR; Huang ES; Hohmann EL; Wang EEL; Oneto C; Cohen SH; Berenson CS; Korman L; Lee C; Lashner B; Kraft CS; Ramesh M; Silverman M; Pardi DS; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L; JAMA Netw Open; 2023 Feb; 6(2):e2255758. PubMed ID: 36780159 [TBL] [Abstract][Full Text] [Related]
16. Identification and engraftment of new bacterial strains by shotgun metagenomic sequence analysis in patients with recurrent Clostridioides difficile infection before and after fecal microbiota transplantation and in healthy human subjects. Verma S; Dutta SK; Firnberg E; Phillips L; Vinayek R; Nair PP PLoS One; 2021; 16(7):e0251590. PubMed ID: 34252073 [TBL] [Abstract][Full Text] [Related]
17. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities. Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161 [TBL] [Abstract][Full Text] [Related]
18. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Kraft CS; Sims M; Silverman M; Louie TJ; Feuerstadt P; Huang ES; Khanna S; Berenson CS; Wang EEL; Cohen SH; Korman L; Lee C; Kelly CR; Odio A; Cook PP; Lashner B; Ramesh M; Kumar P; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L; Pardi DS; Infect Dis Ther; 2024 Jun; ():. PubMed ID: 38941068 [TBL] [Abstract][Full Text] [Related]
19. Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation. Staley C; Kelly CR; Brandt LJ; Khoruts A; Sadowsky MJ mBio; 2016 Dec; 7(6):. PubMed ID: 27999162 [TBL] [Abstract][Full Text] [Related]
20. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Gonzales-Luna AJ; Spinler JK; Oezguen N; Khan MAW; Danhof HA; Endres BT; Alam MJ; Begum K; Lancaster C; Costa GP; Savidge TC; Hurdle JG; Britton R; Garey KW Anaerobe; 2021 Aug; 70():102387. PubMed ID: 34044101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]